ABSTRACT
This study assessed the safety and tolerability of sertindole in the long-term treatment of schizophrenia. An open-label, noncomparative, flexible-dose study was carried out in 11 European countries. Upon completion of an 8-week, haloperidol-referenced randomized clinical trial with sertindole, patients were offered sertindole maintenance treatment up to 18 months. In total, 294 patients were enrolled, of whom 237 (81%) had received sertindole and 57 (19%) had received haloperidol in the lead-in trial. The modal dose during the maintenance period was 16 mg/day. Patients showed therapeutic improvement indicated by significant decreases in the Positive And Negative Syndrome Scale and Clinical Global Impression 'severity-of-illness' scores. An adverse event was the primary reason for withdrawal in 13% of patients. The most common adverse events were fatigue and weight gain, both with incidences of 14%. The incidence of extrapyramidal symptoms was 18%, and 11% of the patients required anticholinergic medication. No statistically significant changes were observed in laboratory values or vital signs, but the mean serum prolactin levels decreased. The mean change in weight from baseline to the last assessment was 2.7 kg. The largest weight increase was observed in patients who were underweight at baseline. Long-term treatment with sertindole was safe and well tolerated, and patients showed clinical improvement beyond acute treatment.
Subject(s)
Antipsychotic Agents/therapeutic use , Haloperidol/therapeutic use , Imidazoles/therapeutic use , Indoles/therapeutic use , Maintenance Chemotherapy/psychology , Schizophrenia/drug therapy , Adolescent , Adult , Aged , Antipsychotic Agents/adverse effects , Female , Humans , Imidazoles/administration & dosage , Imidazoles/adverse effects , Indoles/administration & dosage , Indoles/adverse effects , Maintenance Chemotherapy/methods , Male , Middle Aged , Patient Dropouts/statistics & numerical data , Psychiatric Status Rating Scales/statistics & numerical dataSubject(s)
Antidepressive Agents, Second-Generation/poisoning , Antipsychotic Agents/poisoning , Fluoxetine/poisoning , Imidazoles/poisoning , Indoles/poisoning , Psychotic Disorders/drug therapy , Adult , Antidepressive Agents, Second-Generation/blood , Antipsychotic Agents/blood , Azabicyclo Compounds/poisoning , Blood Pressure/drug effects , Drug Overdose , Female , Fluoxetine/blood , Heart Rate/drug effects , Humans , Hypnotics and Sedatives/poisoning , Imidazoles/blood , Indoles/blood , Piperazines/poisoning , Psychotic Disorders/blood , Suicide, AttemptedABSTRACT
BACKGROUND: It is uncertain whether higher doses of selective serotonin reuptake inhibitors have greater efficacy in generalised anxiety disorder. AIMS: To assess the efficacy of different doses of escitalopram in generalised anxiety disorder. METHOD: Randomised, double-blind, placebo-controlled, fixed-dose, parallel-group, 12-week study, with 681 patients: placebo (n=139); escitalopram, 5 mg/day, (n=134); 10 mg/day (n=136); 20 mg/day (n=133); paroxetine, 20 mg/day (n=139). RESULTS: Mean change in the primary efficacy measure was greater with escitalopram 10 and 20 mg than with placebo; 10 mg was more efficacious than paroxetine. Paroxetine was superior to placebo on some secondary measures, at some time points. Compared with placebo, more patients withdrew because of adverse events with escitalopram 20 mg and paroxetine. CONCLUSIONS: Escitalopram was efficacious in generalised anxiety disorder, 20 was not significantly superior to 10 mg/day. Escitalopram 10 mg was more efficacious than paroxetine.
Subject(s)
Anxiety Disorders/drug therapy , Citalopram/administration & dosage , Paroxetine/administration & dosage , Selective Serotonin Reuptake Inhibitors/administration & dosage , Adult , Aged , Citalopram/adverse effects , Double-Blind Method , Female , Humans , Male , Middle Aged , Paroxetine/adverse effects , Selective Serotonin Reuptake Inhibitors/adverse effects , Treatment OutcomeABSTRACT
RATIONALE: Sertindole is a new atypical antipsychotic drug. Preclinical pharmacology suggests that sertindole has a preferential effect on the activity of limbic and cortical dopaminergic neurons. Clinical trials have shown antipsychotic efficacy and very few extrapyramidal symptoms (EPS) with sertindole at 20 mg/day. OBJECTIVES: This positron emission tomography (PET) study aimed to measure D(2) receptor occupancy in striatal and extra-striatal regions induced by clinically representative doses of sertindole in patients with schizophrenia. METHOD: Four stabilized schizophrenic out-patients received sertindole 20 mg/day for 6-8 weeks. PET was performed using [(11)C]raclopride to measure D(2) receptor occupancy in the striatum and [(11)C]FLB457 to measure occupancy in the neocortex and thalamus, i.e. regions with very low D(2) receptor density. RESULTS: Striatal D(2) receptor occupancy was 52-68%. Similar occupancies were found in the thalamus, and the temporal and frontal cortices. CONCLUSIONS: Sertindole appears efficacious at a low D(2) receptor occupancy, comparable to that produced by clozapine. This finding could explain the low risk of EPS. The functional limbic selectivity of sertindole was not reflected in regional differences in receptor occupancy.